

















  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors - Full Text View - ClinicalTrials.gov</title>
    <link href="/ct2/show/NCT02622321" rel="canonical"/>
    
  <!-- Twitter Card data -->
  <meta name="twitter:card" content="summary">
  <meta name="twitter:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">

  <!-- Open Graph data -->
  <meta property="og:type" content="article" />
  <meta property="og:title" content="A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors - Full Text View - ClinicalTrials.gov">
  <meta property="og:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">
    <meta property="og:description" content="A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors - Full Text View.">
  <meta property="og:url" content="https://clinicaltrials.gov/ct2/show/NCT02622321">
    
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish-vertical.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/glossary.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/base.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/print.css?v=44" media="print" />
  <link rel="stylesheet" href="/ct2/html/css/w3-ct.css?v=44" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/css/w3-ct-oldIE.css?v=44" type="text/css" />
  <![endif]-->
   	
  <link rel="preconnect" href="https://use.fontawesome.com">
  <link rel="preconnect" href="https://www.ncbi.nlm.nih.gov">
  
  <script src="https://use.fontawesome.com/20a31629ec.js"></script>
<!--[if lte IE 7]>
       <link href="/ct2/html/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
<![endif]-->

<style type="text/css">
  h2 
  {
      background-color: #EAEAEA;
  }
</style>
<link href="/ct2/html/css/trial-record.css?v=44" rel="stylesheet" type="text/css" />

	<script type="text/javascript" src="/ct2/html/jquery/js/jquery.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/jquery/js/superclick.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ct.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ctmenu.js?v=44"></script><noscript></noscript>
<script>
var theURL = "/ct2/show/NCT02622321"+window.location.hash;
history.replaceState(null,null,theURL);
</script>

  <meta name="ncbi_sid" content="4ec8b7bc0e309146_36c1a9SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_study"/>
  <meta name="ncbi_pcid" content="NCT02622321"/>
  <meta name="ncbi_ctreqid" content="R9A0Ehzf"/>
  <meta name="ncbi_ctsessid" content="S9A0DT8k"/>
  <meta name="ncbi_ctipid" content="IZ45kPwP"/>
  <meta name="ncbi_cthost" content="w11"/>
</head>


<body> 
<script type="text/javascript">
    jQuery.getScript("https://www.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
      galert(['#alert_banner', 'body &gt; *:nth-child(1)'])});
</script>

<div id="alert_banner"></div>

<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<script type='text/javascript'>
(function(){var g=function(e,h,f,g){
this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
try{(new g(100,"r","QSI_S_ZN_7WHWRcRMBs9xWYd","https://zn7whwrcrmbs9xwyd-nlmenterprise.siteintercept.qualtrics.com/WRSiteInterceptEngine/?Q_ZID=ZN_7WHWRcRMBs9xWYd")).start()}catch(i){}})();
</script><div id='ZN_7WHWRcRMBs9xWYd'><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END WEBSITE FEEDBACK SNIPPET-->
<div id="glossary" class="glossary"
    aria-describedby="glossary-result" aria-hidden="true">
  <button
      title="Close glossary"
      class="js-glossary-close button button--close js-glossary-toggle usa-button-unstyled"
    ><span class="usa-sr-only">Hide glossary</span>
    <i class="fa fa-times" aria-hidden="true"></i>
  </button>
  <h4 class="glossary-heading">Glossary</h4>
  <p>
  Study record managers: refer to the <a href="https://clinicaltrials.gov/ct2/manage-recs/resources#DataElement"><span style="text-decoration:underline">Data Element Definitions</span></a> if submitting registration or results information.
  </p>
  <p>
  <label for="glossary-search" class="label">Search for terms</label>
  </p>
  <span class="clearable-input">
  <input id="glossary-search" class="js-glossary-search">
   <span data-clear-input="" class="js-glossary-clear button js-glossary-toggle usa-button-unstyled">x</span>
  </span>
  <div class="glossary__content" id="glossary-result">
    <ul class="js-glossary-list"></ul>
  </div>
</div>

<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>


<script type="text/javascript" src="/ct2/html/js/working.js"></script><noscript></noscript>
<div id="workingDim" class="ct-dim">
  <div id="workingIndicator" class="ct-workingBox" style="text-align:center;vertical-align:middle;">
    <img alt="Working&#8230;" src="/ct2/html/images/working.gif" height="50" >
  </div>
</div>

<div id="wrapper"> 
<div class="ct-inner_wrapper">   			<a href="/ct2/home" style='float:left;border-bottom-width:0;min-width:200px;width:29%;'><img src='/ct2/html/images/ct.gov-nlm-nih-logo.png' alt='ClinicalTrials.gov'/></a>

				<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
								</ul>
				</div>
    		</div>
  		</div>		
		
<div 
style="float:right;margin-top:1.5%;" 
class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
				<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
				</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div>

</div> 
<div class="ct-outer_breadcrumb w3-container">
	<div id="breadcrumb">
    <ul class="ct-horz-list w3-left">
			<li><a href="/ct2/home">Home</a></li>
												<li><a href="/ct2/results">Search Results</a></li>
										<li>Study Record Detail</li>
    </ul>
    <div id="savedStudies" class="w3-right">
  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
  	<button class="ct-savedStudiesEnabled" id="open-cart-link" type="button" 
  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
  		title="Show previously saved studies.">Saved Studies</button>
  	</div>
</div>
<script type="text/javascript" src="/ct2/html/js/cart.js?v=44"></script><noscript></noscript>

		<script type="text/javascript">
	$(document).ready(function(){
		$("input#saved").prop( 'checked', (inCart("NCT02622321")>=0));
	});
</script>
		<div class="w3-right" style="margin-right: 1em;">
			<label for="saved" title="Add or Remove this study in the Saved Studies list"><input type="checkbox" id="saved" name="NCT02622321" onchange="updateCart('NCT02622321');" style="margin-left:1em;"> Save this study </label>
		</div>
		<div id="maxSavedStudies-popup" class="w3-modal" style="cursor:pointer;border:2px groove" onclick="$('#maxSavedStudies-popup').hide();">
	<div id="maxSavedStudies-popup-content" class="w3-modal-content">
		<div class="w3-display-container" style="border:1px solid #ccc;background-color:#eee;">
			<form>
			<div class="w3-center" style="font-size:large;font-weight:bold;padding:3ex 1.5em;">
				<img src="/ct2/html/images/warning.png" alt="Maximum Saved Studies Reached" style="max-width:1.0rem;cursor:pointer;"/>
			    <b>Warning</b>
				<div style="margin-top:1ex;margin-bottom:0.5ex;">You have reached the maximum number of saved studies (100).</div>
				<div>Please remove one or more studies before adding more.</div>
			</div>
		
			<div class="w3-center" style="padding-bottom:1.5ex">
			  <input class="ct-searchButton" type="button" style="opacity:1.0;font-weight:bold;font-size:inherit;padding:1.1ex 1em;" onclick="$('#maxSavedStudies-popup').hide();" value="Close" title="Close this dialog"/>
			</div>
			</form>
		</div>
	</div>
</div>

	</div>
</div>

<div style="clear:both;"></div>

<div id="main-content" tabindex='-1'>
	
	
		<div class="tr-indent2">
        	<h1 class="tr-h1 ct-sans-serif tr-solo_record">A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)</h1>

  <div class="w3-row">
    <div class="w3-col m6">       <div class="usa-alert usa-alert-warning" style="clear:both;margin:2ex 2em;">
        <table>
          <tr>
            <td style="width:5%">
              <img src="/ct2/html/images/warning.png" style="width:1.3em;" alt=""/>
            </td>
            <td style="padding-right:2em;">
              The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
                            Read our <a href="/ct2/about-site/disclaimer">disclaimer</a> for details.
            </td>
          </tr>
        </table>
      </div>      </div> 
<!--
  <div style="float:right;margin-right:4em">ClinicalTrials.gov Identifier: NCT02622321</div>
-->
  <div class="w3-col m1">&nbsp;</div> 
  <div class="w3-col m5">   <table style="width:95%">
  <tr><td>ClinicalTrials.gov Identifier: NCT02622321</td>
  </tr>
  <tr><td>
      
       
              <div  class="tr-status tr-not-recruiting-colors" >
                        <span style="display:inline;" class="term" data-term="Recruitment Status" title="Show definition">Recruitment Status <i class="fa fa-info-circle term" aria-hidden="true" data-term="Recruitment Status" style="border-bottom-style:none;"></i></span> : 
                    Completed
                  
                
  <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="First Posted" title="Show definition">First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="First Posted" style="border-bottom-style:none;"></i></span> : December 4, 2015</div>
      <div style="font-size:inherit">
    <span style="display:inline;" class="term" data-term="Results First Posted" title="Show definition">Results First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Results First Posted" style="border-bottom-style:none;"></i></span> : November 24, 2017</div>
    <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="Last Update Posted" title="Show definition">Last Update Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Last Update Posted" style="border-bottom-style:none;"></i></span> : June 24, 2021</div>

  
      </div>
  </td>
  </tr>
  </table>
  </div>
  </div>


                <div class="tr-info-title">Sponsor:</div>
                <div class="tr-info-text" id="sponsor"> Hoffmann-La Roche </div>
                <div class="tr-info-title">Collaborator:</div>
                                  				  				                                    <div class="tr-info-text" id="sponsor1">Chugai Pharmaceutical</div> 
                  				  
                              <div class="tr-info-title">Information provided by (Responsible Party):</div>
                <div class="tr-info-text" id="responsibleparty">Hoffmann-La Roche</div>
              	</div>
<br>


<div id="tabs">
    <ul id="tab-links">
		<li id="full-text"  class="current">Study Details     </li>
		<li id="tabular"   ><a href="/ct2/show/record/NCT02622321" >Tabular View</a></li>
  					<li id="results"   ><a href="/ct2/show/results/NCT02622321">Study Results</a></li>
						<li id="disclaimer"><a title="Disclaimer - opens new window"  href="/ct2/about-site/disclaimer" onclick="openNewWindow('/ct2/about-site/disclaimer'); return false"
>Disclaimer</a></li>
		<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
    </ul>
</div>  <!--
<div style="background-color:#f6f6f6;margin-top:5.0ex;padding-bottom:1.5ex;"> </div>
-->
		
	<div id="tab-body">
		<div class="tr-indent2" style="background-color:white;">
						  
<!-- purpose_section -->
<div class="tr-indent1" style="margin-top:1ex">

<div class="tr-subsection">
	<div class="ct-header2"><a id="studydesc"></a>Study Description</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

<div class="tr-indent2" style="margin-top:2ex">

  <div class="ct-body3">Brief Summary:</div>
  <div class="ct-body3 tr-indent2">This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [&lt;] 9 or greater than or equal to [&gt;/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).</div><br/>

    <!-- condition, intervention, phase summary table -->
  <table class="ct-data_table tr-data_table" border="1" style="margin:auto;width:80%;">
    <tr style="text-align:left;">
            <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Condition/disease" title="Show definition">Condition or disease <i class="fa fa-info-circle term" aria-hidden="true" data-term="Condition/disease" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Phase" title="Show definition">Phase <i class="fa fa-info-circle term" aria-hidden="true" data-term="Phase" style="border-bottom-style:none;"></i></span>       </th>
          </tr>
    <tr style="text-align:left;vertical-align:top;">
            <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Hemophilia A</span>
              </td>
                  <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Drug: Emicizumab</span>
                <span style="display:block;margin-bottom:1ex;">Drug: rFVIIa</span>
                <span style="display:block;margin-bottom:1ex;">Drug: aPCC</span>
              </td>
                  <td class="ct-body3" style="white-space:nowrap;">
                <span style="display:block;margin-bottom:1ex;">Phase 3</span>
              </td>
          </tr>
  </table>
  <br/>
  
      <span style="display:inline;" class="term" data-term="Expanded Access" title="Show definition">Expanded Access <i class="fa fa-info-circle term" aria-hidden="true" data-term="Expanded Access"></i></span>: An investigational treatment associated with this study has been <span style="color:green">approved</span> for sale to the public. &nbsp;
          <a class="ct-header3 tr-tr-study-link" title="Show expanded access study" href="/ct2/show/NCT03154437" 
      onclick="openPopupWindow('/ct2/show/NCT03154437',false); return false;">More info ...</a>
        <br/>
    <br/>
  
  </div> 
<div class="tr-subsection">
  <div class="ct-header2"><a id="studydesign"></a>Study Design</div>
  <div class="tr-underline"></div>
  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

  <p>
  <table class="ct-layout_table tr-tableStyle tr-studyInfo" style="margin-bottom:2ex;">
   <caption>Layout table for study information</caption>
   <thead>
    <tr>
      <th id="studyInfoColTitle"></th>
      <th id="studyInfoColData"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="studyInfoColTitle">
<span style="display:inline;" class="term" data-term="Study Type" title="Show definition">Study Type <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Type" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">
        Interventional
                &nbsp;(Clinical Trial)
                
        
      </td>
    </tr>
                    <tr>
      <td headers="studyInfoColTitle">Actual
<span style="display:inline;" class="term" data-term="Enrollment" title="Show definition">Enrollment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Enrollment" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">113 participants</td>
    </tr>
                <tr>
            <td headers="studyInfoColTitle">Allocation:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Randomized</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Intervention Model:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Parallel Assignment</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Masking:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> None (Open Label)</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Primary Purpose:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> Treatment</td>
    </tr>
                    <tr>
<!--
      <td headers="studyInfoColTitle" style="padding-top:2ex;">Official Title:</td>
-->
      <td headers="studyInfoColTitle">Official Title:</td>
      <td headers="studyInfoColData" style="padding-left:1em;">A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors</td>
    </tr>
    
            <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Study Start Date" title="Show definition">Study Start Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Start Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">November 18, 2015</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Primary Completion Date" title="Show definition">Primary Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">October 25, 2016</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Study Completion Date" title="Show definition">Study Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">December 1, 2020</td>
      </tr>
            </tbody>
    </table>

    <!-- NLM links -->
<p>
<div class="tr-indent2">
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Resource links provided by the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>

    <!-- ghr links -->
  <div style="margin-bottom:2ex">
    <a class="tr-study-link" href="https://medlineplus.gov/genetics/" title="MedlinePlus Genetics" onclick="openNewWindow('https://medlineplus.gov/genetics/'); return false">MedlinePlus Genetics</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/genetics/condition/hemophilia" title="Hemophilia at Genetics Home Reference" onclick="openNewWindow('https://medlineplus.gov/genetics/condition/hemophilia'); return false">Hemophilia</a>
	          </div>
  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://medlineplus.gov/" title="MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/'); return false">MedlinePlus</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/hemophilia.html" title="Hemophilia at MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/hemophilia.html'); return false">Hemophilia</a>
	          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://druginfo.nlm.nih.gov/drugportal" title="Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal'); return false">Drug Information</a> available for:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab" title="Emicizumab at Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab'); return false">Emicizumab</a>
	          </div>
  
    <!-- ORD links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://rarediseases.info.nih.gov/gard" title="Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/gard'); return false">Genetic and Rare Diseases Information Center</a> resources:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/10418/hemophilia" title="Hemophilia at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/10418/hemophilia'); return false">Hemophilia</a>
	        	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a" title="Hemophilia&#160;A at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a'); return false">Hemophilia&#160;A</a>
	          </div>
  
  
  <!-- Ropr Link -->
<!-- Commented out RoPR
  -->

  <div style="margin-bottom:2ex;">
  <a class="tr-study-link" href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>
  </div>

  </div>
</div>


  
  <br/>
    </div>

    <!-- arms and groups table -->
    		<div class="tr-subsection">
		    		    	<div class="ct-header2"><a id="armgroup"></a>Arms and Interventions</div>
		    		    <div class="tr-underline"></div>
			<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
		</div>
	
    <div style="padding-left:.8em; padding-right:1.2em;text-align:left;">
        <p>
    <table class="ct-data_table tr-data_table" style="padding:5px;width:100%;border-width:1px;">
      <thead>
      <tr style="text-align:left;">
        <th class="ct-header3 tr-pale_banner_color" style="width:50%;">
            				<span style="display:inline;" class="term" data-term="Arm" title="Show definition">Arm <i class="fa fa-info-circle term" aria-hidden="true" data-term="Arm" style="border-bottom-style:none;"></i></span> 			        </th>
                <th class="ct-header3 tr-pale_banner_color">
			<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>         </th>
              </tr>
      </thead>
      <tbody>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Arm A: 1.5 mg/kg Emicizumab QW
<div class="tr-indent2" style="margin-top:0.5ex">Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                      Drug: rFVIIa
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive rFVIIa.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: NovoSeven&#174;</div><br/>
                      Drug: aPCC
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive aPCC.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: Factor Eight Inhibitor Bypassing Activity (FEIBA&#174;)</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Active Comparator: Arm B (Control): No Prophylaxis, Then Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                      Drug: rFVIIa
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive rFVIIa.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: NovoSeven&#174;</div><br/>
                      Drug: aPCC
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive aPCC.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: Factor Eight Inhibitor Bypassing Activity (FEIBA&#174;)</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Arm C: 1.5 mg/kg Emicizumab QW
<div class="tr-indent2" style="margin-top:0.5ex">Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                      Drug: rFVIIa
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive rFVIIa.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: NovoSeven&#174;</div><br/>
                      Drug: aPCC
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive aPCC.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: Factor Eight Inhibitor Bypassing Activity (FEIBA&#174;)</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Arm D: 1.5 mg/kg Emicizumab QW
<div class="tr-indent2" style="margin-top:0.5ex">Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>RG6013</li>
<li>ACE910</li>
</ul>
</div><br/>
                      Drug: rFVIIa
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive rFVIIa.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: NovoSeven&#174;</div><br/>
                      Drug: aPCC
<div class="tr-indent2" style="margin-top:0.5ex">Participants will continue to receive aPCC.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Name: Factor Eight Inhibitor Bypassing Activity (FEIBA&#174;)</div><br/>
                  </td>
              </tr>
            </tbody>
    </table>
          </div>
    <br/>

    
    <!-- more details -->
  <br/>
  <div class="tr-subsection">
	  <div class="ct-header2"><a id="outcomemeasures"></a>Outcome Measures</div>
	  <div class="tr-underline"></div>
	  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  <br/>
  <div class="tr-indent3" style="margin-right:1em;">

        <!-- primary outcomes -->
    <div class="ct-body3">
<span style="display:inline;" class="term" data-term="Primary Outcome Measure" title="Show definition">Primary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            	<li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a &quot;treatment for bleed&quot;. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            </ol>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="ct-body3"  style="margin-right:1em;">
<span style="display:inline;" class="term" data-term="Secondary Outcome Measure" title="Show definition">Secondary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Secondary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents [&nbsp;Time&nbsp;Frame:&nbsp;Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents [&nbsp;Time&nbsp;Frame:&nbsp;Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This was an intra-participant comparison of the ABRs for treated bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a &quot;treatment for bleed&quot;. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated joint bleeds were defined as treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Bleeds due to surgery/procedure were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents [&nbsp;Time&nbsp;Frame:&nbsp;Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm C participants who had previously received prophylactic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents [&nbsp;Time&nbsp;Frame:&nbsp;Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This was an intra-participant comparison of the ABRs for treated bleeds in Arm C participants who had previously received bypassing agent prophylaxis during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a &quot;treatment for bleed&quot;. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated target joint bleeds included treated (with coagulation factors) joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With 0 Bleeds for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (&gt;/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health).</div><br/>
            <li style="margin-top:0.7ex;">Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (&gt;/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Questionnaire Total Score is the average of the all domain scores and range from 0 to 100, with lower scores reflective of better quality of life.</div><br/>
            <li style="margin-top:0.7ex;">European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</div><br/>
            <li style="margin-top:0.7ex;">EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis [&nbsp;Time&nbsp;Frame:&nbsp;Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single utility index value ranging from 1 to 5, where 1 indicates better health state (no problems) and 5 indicates worst health state (confined to bed).</div><br/>
            <li style="margin-top:0.7ex;">Hemophilia-Specific Quality of Life - Short Form (Haemo-Qol-SF) Questionnaire Total Score at Baseline and Week 25 in Adolescent Participants (12-17 Years Old) [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and Week 25 (for Arm B (Emi), Study Weeks are relative to first emicizumab dose)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life. Baseline was defined as the last assessment prior to treatment. Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose; baseline for Arm B (Emi) is the same as Week 25 for Arm B (Control).</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (&gt;/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants [&nbsp;Time&nbsp;Frame:&nbsp;1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.</div><br/>
            <li style="margin-top:0.7ex;">Safety Summary of the Overall Number and Percentage of Participants With at Least One Adverse Event, Severity Assessed According to the WHO Toxicity Grading Scale [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms &quot;severe&quot; and &quot;serious&quot; are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated, only data before up-titration is included. aPCC = activated prothrombin complex concentrate; Hypersens.= hypersensitivity</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a &#8805;4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a &#8805;4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample. ADA-positive samples were further analyzed for neutralizing capacity using a modified FVIII chromogenic assay; if also positive, they were considered neutralizing ADAs.</div><br/>
            <li style="margin-top:0.7ex;">Plasma Trough Concentrations of Emicizumab at Specified Timepoints [&nbsp;Time&nbsp;Frame:&nbsp;Pre-dose (0 hour [hr]) on Weeks 1-5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, and 169 (For Arm B (Emi), Study Weeks are relative to first emicizumab dose)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose.</div><br/>
            </ol>
    </div>
    <br/>
    
    
    
  </div>
  
			  
<!-- eligibility_section -->
<div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
<div class="tr-subsection">
	<div class="ct-header2"><a id="eligibility"></a>Eligibility Criteria</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>

<p>
  <div class="tr-indent2 usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a href="/ct2/about-studies/learn" title="Learn About Clinical Studies"><u>Learn About Clinical Studies.</u></a>
    </em>
  </div>


  <br/>
  <div class="tr-indent2">
    <table class="ct-layout_table tr-tableStyle tr-studyInfo">
      <caption>Layout table for eligibility information</caption>
      <thead>
        <tr>
          <th id="elgType"></th>
          <th id="elgData"></th>
        </tr>
      </thead>
      <tbody>
            <tr>
        <td headers="elgType" class="ct-nowrap">Ages Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">12 Years and older &nbsp; (Child, Adult, Older Adult)</td>
      </tr>
                  <tr>
        <td headers="elgType" class="ct-nowrap">Sexes Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">All</td>
      </tr>
                              <tr>
        <td headers="elgType" class="ct-nowrap">Accepts Healthy Volunteers: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">No</td>
      </tr>
                  </tbody>
    </table>

    
        <div class="ct-header3" style="margin-top:2ex">Criteria</div>
    <div class="tr-indent2"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Body weight &gt;/= 40 kilograms (kg) at the time of screening</li>
    <li style="margin-top:0.7ex;">Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor ( that is [i.e.], &gt;/= 5 Bethesda Units [BU])</li>
    <li style="margin-top:0.7ex;">Documentation of treatment with episodic or prophylactic bypassing agents for at least the last 24 weeks</li>
    <li style="margin-top:0.7ex;">&gt;/= 6 bleeds in the last 24 weeks prior to screening (if on an episodic bypassing agent regimen) or &gt;/=2 bleeds in the last 24 weeks prior to screening (if on a prophylactic bypassing agent regimen)</li>
    <li style="margin-top:0.7ex;">Adequate hematologic, hepatic and renal function</li>
    <li style="margin-top:0.7ex;">For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use single or combined highly effective contraceptive methods</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Participants with inherited or acquired bleeding disorder other than hemophilia A</li>
    <li style="margin-top:0.7ex;">Participants with ongoing (or plan to receive during the study) immune tolerance induction therapy or prophylaxis with Factor VIII (FVIII), with the exception of participants who have received a treatment regimen of FVIII prophylaxis with concurrent bypassing agent prophylaxis</li>
    <li style="margin-top:0.7ex;">Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which antithrombotic treatment is not currently ongoing) or current signs of thromboembolic disease</li>
    <li style="margin-top:0.7ex;">Participants with other conditions (for example [e.g.], certain autoimmune diseases) that may increase the risk of bleeding or thrombosis</li>
    <li style="margin-top:0.7ex;">History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection</li>
    <li style="margin-top:0.7ex;">Known human immunodeficiency virus (HIV) infection with cluster of differentiation 4 (CD4) count &lt; 200 cells per microliter (cells/mcL) within 24 weeks prior to screening</li>
    <li style="margin-top:0.7ex;">Use of systemic immunomodulators (e.g., interferon or rituximab) at enrolment or planned use during the study, with the exception of antiretroviral therapy</li>
    <li style="margin-top:0.7ex;">Participants who are at high risk for thrombotic microangiopathy (TMA; e.g., have a previous medical or family history of TMA), in the investigator's judgment</li>
    <li style="margin-top:0.7ex;">Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the participant's safe participation in and completion of the study or interpretation of the study results</li>
    <li style="margin-top:0.7ex;">Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study</li>
    <li style="margin-top:0.7ex;">Receipt of emicizumab in a prior investigational study; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration; A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter; An investigational drug concurrently</li>
    <li style="margin-top:0.7ex;">Unwillingness to use highly effective contraception methods for the specified duration in the protocol (females only, unless required otherwise by the local health authority)</li>
    <li style="margin-top:0.7ex;">Clinically significant abnormality on screening evaluations or laboratory tests that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant</li>
    <li style="margin-top:0.7ex;">Pregnancy or lactation, or intent to become pregnant during the study</li>
  </ul></div>
    
  </div>

  </div>

			  
<!-- location_section -->
<a id="contacts"></a>
<div class="tr-indent1" style="margin-top:3ex">
<div class="tr-subsection">
	<div class="ct-header2"><a id="contactlocation"></a>Contacts and Locations</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>


<div class="tr-indent2" style="margin-top:2ex">

<!--
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 
For general information, see <a href="/ct2/about-studies/learn" target="def_win" onClick="openNewWindow('/ct2/about-studies/learn'); return false;" title="Learn About Clinical Studies - opens new window"><u>Learn About Clinical Studies.</u></a>
<br/>
-->

  
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>
    To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
    </em>
    <p>
    <em>
    Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT02622321</strong>
    </em>
  </div>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
   <a id="locn"></a>
  <div class="ct-header3" style="margin-top:2ex;margin-bottom:2ex;">Locations</div>

      <script type="text/javascript" async src="/ct2/html/js/ExpandCollapseScript.js"></script>
    
    <span id="EXPAND_CONTROL-Locations" class="EXPAND tr-showAndHide"       onclick="toggleSectionAndControls('-Locations');document.getElementById('locn').scrollIntoView({behavior: 'smooth', block: 'start'});" 
      title="Show 44 study locations">
      <img src="/ct2/html/images/expand.png" alt="Show">
      <span style="padding-bottom:3px"> Show 44 study locations</span>
    </span>
    <span  id="COLLAPSE_CONTROL-Locations" class="COLLAPSE tr-showAndHide" style="display:none"      onclick="toggleSectionAndControls('-Locations');" 
      title="Hide 44 study locations">
      <img src="/ct2/html/images/collapse.png"  alt="Hide">
      <span style="padding-bottom:3px"> Hide 44 study locations</span>
    </span>
     
  <div id="COLLAPSE-Locations" class="COLLAPSE" style="display:none">
        <div class="tr-table_cover">
      <table class="ct-layout_table tr-indent2">
        <caption>Layout table for location information</caption>
        <thead>
          <tr>
            <th id="locName"></th>
            <th id="locStatus"></th>
          </tr>
        </thead>
        <tbody>
                                    <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, California</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Children's Hospital Los Angeles</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Los Angeles, California, United States, 90010  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Santa Monica Oncology Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Santa Monica, California, United States, 90403  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Colorado</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">University of Colorado Denver, Children's Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Aurora, Colorado, United States, 80045  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Georgia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Winship Cancer Institute</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Atlanta, Georgia, United States, 30322  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Massachusetts</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Boston Childrens Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Boston, Massachusetts, United States, 02115  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Michigan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Children's Hospital of Michigan; Pediatrics</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Detroit, Michigan, United States, 48201  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, New York</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Cornell Univ Medical College; Hematology-Oncolog</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">New York, New York, United States, 10021  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Oregon</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Oregon Health &amp; Science Uni ; Dept of Pediatrics</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Portland, Oregon, United States, 97201  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Pennsylvania</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Hershey, Pennsylvania, United States, 17033-0850  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Texas</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Houston, Texas, United States, 77030  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Washington</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Seattle, Washington, United States, 98104  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, New South Wales</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Royal Prince Alfred Hospital; Haematology</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Camperdown, New South Wales, Australia, 2050  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, Victoria</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Melbourne, Victoria, Australia, 3004  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Costa Rica</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">ICIC</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">San Jose, Costa Rica, 1000  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">France</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bron, France, 69677  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">CH de Bicetre; Centre de Traitement d' Hemophilie</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Le Kremlin Bicetre, France, 94275  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hopital Cardiologique; Hematologie B</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Lille, France, 59037  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Groupe Hospitalier Necker Enfants Malades</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Paris, France, 75015  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Germany</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Universit&#228;tsklinikum Bonn; Institut f&#252;r Experimentelle H&#228;matologie und Transfusionsmedizin</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bonn, Germany, 53127  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">CTC North GmbH &amp; Co. KG am Universit&#228;tsklinikum Hamburg-Eppendorf</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Hamburg, Germany, 20251  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">H&#228;mophilie-Zentrum Rhein Main GmbH</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">M&#246;rfelden-Walldorf, Germany, 64546  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Italy</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi &quot;Angelo Bianchi e Bonomi&quot;</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Milano, Lombardia, Italy, 20122  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">AOU Careggi; SOD Malattie Emorragiche</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Firenze, Toscana, Italy, 50134  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Japan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Nagoya University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Aichi, Japan, 466-8560  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hiroshima University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Hiroshima, Japan, 734-8551  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hyogo College of Medicine Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Hyogo, Japan, 663-8501  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">St. Marianna University School of Medicine Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Kanagawa, Japan, 216-8511  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital of the University of Occupational and Environmental Health,Japan</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Kitakyushu-shi, Japan, 807-8556  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Nara Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Nara, Japan, 634-8522  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Tokyo Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Tokyo, Japan, 160-0023  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Korea, Republic of</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Severance Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Seoul, Korea, Republic of, 03722  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">New Zealand</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Auckland City Hospital; Auckland Haemophilia Centre</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Auckland, New Zealand, 1023  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Poland</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Gdansk, Poland, 80-952  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">SPSK Nr1 Klinika Hematoo&amp;Transpl.Szpiku</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Lublin, Poland, 20-081  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">ALVAMED Lekarskie Gabinety Specjalistyczne</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Pozna&#324;, Poland, 60-549  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Instytut Hematologii i Transfuzjologii; Klinika Zaburze&#324; Hemostazy i Chor&#243;b Wewn&#281;trznych</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Warsaw, Poland, 02-776  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">South Africa</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Johannesburg, South Africa, 2193  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Spain</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Paz; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Madrid, Spain, 28046  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario Virgen del Rocio; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Sevilla, Spain, 41013  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Fe; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Valencia, Spain, 46026  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Taiwan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">National Taiwan Uni Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Taipei City, Taiwan, 10041  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United Kingdom</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Cardiff and Vale NHS Trust</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Cardiff, United Kingdom, CF14 4XW  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">St Thomas' Hospital; Haemostasis &amp; Thromboisis Centre</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">London, United Kingdom, SE1 7EH  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Oxford University Hospitals NHS Trust - Churchill Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Oxford, United Kingdom, OX3 7LE  </td></tr>
                                          </tbody>
      </table>
    </div>
  </div>   
  
  <!-- sponsors -->
      <div class="ct-header3" style="margin-top:2ex">Sponsors and Collaborators</div>
              <div class="tr-indent2" style="margin-top:1ex">Hoffmann-La Roche</div>
              <div class="tr-indent2" style="margin-top:1ex">Chugai Pharmaceutical</div>
        
  <!-- overall officials -->
    <div class="ct-header3" style="margin-top:2ex">Investigators</div>
  <div class="tr-table_cover">
  <table class="ct-layout_table tr-indent2">
    <caption>Layout table for investigator information</caption>
    <thead>
    <tr>
      <th id="role" style="visibility:hidden"></th>
      <th id="name" style="visibility:hidden"></th>
      <th id="affiliation" style="visibility:hidden"></th>
      <th id="address" style="visibility:hidden"></th>
    </tr>
    </thead>
        <tr>
      <td headers="role">Study Director:</td>
      <td headers="name">Clinical Trials</td>
            <td headers="affiliation">Hoffmann-La Roche</td>
            <td headers="address"></td>
    </tr>
      </table>
  </div>
  

</div>
</div>
						
<!-- more_info_section -->

<!-- Large docs section -->

    

<!-- More info section -->
  <div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
  <div class="tr-subsection">
  	<div class="ct-header2"><a id="moreinfo"></a>More Information</div>
  	<div class="tr-underline"></div>
  	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  
  <div class="tr-indent2" style="margin-top:1em;">


    <!-- Additional Information -->
    

    <!-- Available Study Data/Document -->
    

  <!-- References -->
    
    
  <!-- Derived References -->
        <span class="ct-header3">Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):</span>
      <div class="tr-indent2">
                <div style="margin-top:2ex">
                    <a href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0JcKCjLgCwA6h9Ei4L3BUgWwNG0it." title="Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0JcKCjLgCwA6h9Ei4L3BUgWwNG0it.'); return false">Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.</a>
                            </div>
              </div>
      <br/>
    
   
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex;">
    <caption>Layout table for additonal information</caption>
    <thead>
    <tr>
      <th id="colTitle1"></th>
      <th id="colData1"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Responsible Party:</td>
      <td headers="colData1" style="padding-left:1em">Hoffmann-La Roche</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">ClinicalTrials.gov Identifier:</td>
      <td headers="colData1" style="padding-left:1em">
        <a class="tr-study-link" title="Current version of study NCT02622321 on ClinicalTrials.gov" href="https://clinicaltrials.gov/show/NCT02622321">NCT02622321</a> &nbsp; &nbsp;

  <script type="text/javascript">
    <!--
    // Scramble access to archive site -
    // don't want crawlers directing users to outdated versions of the study
    // this should be opaque to crawlers that don't execute javascript
    var yyy=new Array(
      ['<','a clas','s="tr-study','-link c', 't-now','rap" t','itle="Hist','orical vers','ions of '],
      ['study ','NCT02622321',' on Clin','icalTrials.','go'],
      ['v Ar','chive',' Sit','e" ','onc','lick="','openN','ewWin', 'dow(','\'/ct2/', 'history/'],
      ['NCT02622321','\'); return', ' false;" '],
      ['href','="/ct2/','history/','NCT02622321"','>'],
      ['Histo','ry of C','hange','s<','/','a>']);
    var i=0;
    var j=0;
    var xxx='';
    for (i=0; i<yyy.length; i++)
      for (j=0; j<yyy[i].length; j++)
        xxx+=yyy[i][j];
    document.write(xxx)
    -->
  </script>

      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Other Study ID Numbers:</td>
      <td headers="colData1" style="padding-left:1em">
                                    BH29884 <br/>
                                                2015-002866-21 ( EudraCT Number )<br/>
                            </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">First Posted:</td>
      <td headers="colData1" style="padding-left:1em">December 4, 2015
          &nbsp;&nbsp;
          <a class="tr-study-link ct-nowrap" href="/ct2/keydates/NCT02622321"
                title="View key record dates for NCT02622321"
                onclick="openNewWindow('/ct2/keydates/NCT02622321'); return false;">Key Record Dates</a>
      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Results First Posted:</td>
      <td headers="colData1" style="padding-left:1em">November 24, 2017</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Update Posted:</td>
      <td headers="colData1" style="padding-left:1em">June 24, 2021
      </td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Verified:</td>
      <td headers="colData1" style="padding-left:1em">May 2021
      </td>
    </tr>
           
    <!-- Plan to Share Data -->
        </tbody>
  </table>

    <br/>
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex">
    <caption>Layout table for additional information</caption>
    <thead>
    <tr>
      <th id="colTitle2"></th>
      <th id="colData2"></th>
    </tr>
    </thead>
    <tbody>       
        <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Drug Product:</td>
      <td headers="colData2" style="padding-left:1em">Yes</td>
    </tr>
            <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Device Product:</td>
      <td headers="colData2" style="padding-left:1em">No</td>
    </tr>
                    </tbody>
  </table>
  
  
    <!-- keywords -->
    
    <!-- mesh terms -->
          <div class="tr-tableLabel">Additional relevant MeSH terms:</div>
      <div class="tr-indent3">
        <table class="ct-layout_table tr-meshTerms" style="width:100%;">
          <caption>Layout table for MeSH terms</caption>
          <thead>
          <tr>
            <th id="meshTermCol1" style="width:50%;"></th>
            <th id="meshTermCol2"></th>
          </tr>
          </thead>
          <tr>
            <td headers="meshTermCol1" style="padding-left:1em;">
                            Hemophilia A<br/>
                            Blood Coagulation Disorders, Inherited<br/>
                            Blood Coagulation Disorders<br/>
                            Hematologic Diseases<br/>
                            Coagulation Protein Disorders<br/>
                          </td>
                        <td headers="meshTermCol1" style="padding-left:1em;">
                            Hemorrhagic Disorders<br/>
                            Genetic Diseases, Inborn<br/>
                            Anti-inhibitor coagulant complex<br/>
                            Coagulants<br/>
                          </td>
                      </tr>
        </table>
      </div>
    
  <br/>

  <!--
        <span class="ct-body3">ClinicalTrials.gov processed this record on July 02, 2021</span><br/>
      -->
    <br/>  
  </div>
   </div>
						
			<div id="to-top"><a href="#wrapper">To Top</a></div>
			
			<div style="clear:both;"></div>
		</div>
	</div>
</div>  
<div>       <div id="for-footer">
        <ul class="ct-horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

</div>  
<div id="footer-menu">
    <ul class="ct-horz-list">
		<li><a     href="/ct2/home">Home</a></li>
		<li><a     href="/ct2/resources/rss">RSS Feeds</a></li>
		<li><a     href="/ct2/sitemap">Site Map</a></li>
		<li><a     href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
		<li><a     href="/ct2/about-site/disclaimer">Disclaimer</a></li>
		<li><a     href="https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02622321" onclick="openNewWindow('https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02622321'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="ct-horz-list">
		<li ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li ><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="ct-horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

<script type="text/javascript">__ncbi_sg_gaMode="clinicaltrials"</script>
<script type="text/javascript" src="/ct2/html/js/instrumentNCBIBaseJS.min.js?v=2"></script><noscript></noscript>
<script type="text/javascript" src="/ct2/html/js/main-glossary.js?v=44"></script><noscript></noscript>
<script type="text/javascript">
//OnSubmit routine - copy over some useful data and submit
function sendSearchPing() {
// Get pinger values
var cVals = ncbi.sg.getInstance()._cachedVals;
var app = cVals['ncbi_app'];
var db = cVals['ncbi_db'];
var pdid = cVals['ncbi_pdid'];
var pcid = cVals['ncbi_pcid'];
// Populate search details
var searchDetails = {};
searchDetails['jsevent'] = 'search';
searchDetails['searchtext'] = jQuery('#header-search-query').val();
if (app!=null) searchDetails['ncbi_app'] = app.value;
if (db!=null) searchDetails['ncbi_db'] = db.value;
if (pdid!=null) searchDetails['ncbi_pdid'] = pdid.value;
if (pcid!=null) searchDetails['ncbi_pcid'] = pcid.value;
// Send ping msg
ncbi.sg.ping(searchDetails);
};
</script>


</body>
</html>
